DGK Herztage 2017

Poster

Cholesterinmetabolismus und Therapie

Diskussionsleiter: U. Laufs (Leipzig)

	(P532)	Altered Platelet Lipidome Influences Atherothrombotic Disposition: Implications for Coronary Artery Disease and Regulation by CXCL12-CXCR4-CXCR7 Axis
		M. Chatterjee, D. Rath, J. Schlotterbeck, T. E. Schäffer, M. Lämmerhofer, M. Gawaz (Tübingen)
	(P533)	Detailed analysis of cholesterol metabolism predicts cardiovascular events in patients admitted for coronary angiography
		O. Weingärtner, D. Lütjohann, B. Cremers, S. Seiler-Mußler, H.-F. Schött, A. Kerksiek, S. Meyer, A. Zawada, U. Laufs, B. Scheller, D. Fliser, M. Böhm, G. Heine (Oldenburg, Bonn, Homburg/Saar, Homburg)
	(P534)	Benefit of the PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis one-year follow up
		K.-P. Mellwig, D. Horstkotte, F. van Buuren (Bad Oeynhausen)
	(P535)	The PEARL non-interventional study on real-world use of alirocumab in German clinical practice – rationale, design and interim data from the first 247 patients
		K. Parhofer, B. von Stritzky, W. D. Paar (München, Berlin)
	(P536)	Platelet Oxidised LDL as a Prognostic Biomarker for Symptomatic Coronary Artery Disease
		D. Rath, M. Chatterjee, A.-S. Böhm, T. Geisler, M. Gawaz (Tübingen)